Haematopoietic stem cell transplantation in systemic sclerosis

Area of Science:

• Immunology
• Rheumatology
• Hematology

Background:

• Systemic sclerosis (SSc) is a severe autoimmune disease with limited treatment options.
• Standard care for SSc often leads to disease progression and organ damage.
• Hematopoietic stem cell transplantation (HSCT) has emerged as a potential therapeutic strategy.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of HSCT in patients with systemic sclerosis.
• To compare HSCT outcomes against standard of care in randomized controlled trials.
• To identify optimal patient selection criteria for HSCT in SSc.

Main Methods:

• Analysis of three randomized controlled trials (RCTs) comparing HSCT to standard care in SSc.
• Assessment of survival, forced vital capacity, skin thickening, vasculopathy, and quality of life.
• Evaluation of transplant-related mortality and adverse events.

Main Results:

• HSCT demonstrated significant long-term survival benefits and sustained improvements in lung function, skin, and quality of life compared to standard care.
• Control groups receiving standard care showed clinical decline.
• Increased transplant-related mortality and risks of secondary autoimmune diseases and gonadal failure were noted.

Conclusions:

• HSCT offers significant benefits for carefully selected, early-stage, rapidly progressive diffuse SSc patients with poor prognosis but without advanced organ involvement.
• The potential for drug-free remission exists, but relapse necessitates further treatment.
• Weighing benefits against risks, HSCT is a viable option for a specific SSc patient subset.